MENLO THERAPEUTICS: Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults
Latest News
ELI LILLY AND COMPANY: Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study